Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach

A pragmatic and successful approach to treating nonsmall‐cell lung carcinoma

“…The outcomes from this data collection period are consistent with Inova's results from 1981 through 1989 5 , 6 . The results match or exceed the best results for treatment of late‐stage (ie, III and IV) disease reported anywhere to date 7 , 8 …”

Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001)

“…Those studies indicated that perioperative morbidity ranged from 18% to 46%, and postoperative mortality ranged from 0% to 7%. 9,10,[23][24][25][26][27] The current trial has several limitations. This was a single-institution study, and the sample size was relatively small.…”

“…Our perioperative results are comparable to those reported in previous neoadjuvant studies for locally advanced NSCLC. Those studies indicated that perioperative morbidity ranged from 18% to 46%, and postoperative mortality ranged from 0% to 7% …”

Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer

“…Finally, the inclusion of a safe surgical approach for those patients satisfying eligibility criteria is based on our own experience [34] and others' [35] suggesting that, in selected T4 cases the ''inductive potential'' of any chemo and/or radio-chemotherapy treatment should be carefully matched with surgical indication based on clinical re-staging evidences.…”